Trial Profile
A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Nov 2023
Price :
$35
*
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ivosidenib (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer
- Focus Adverse reactions
- 21 Nov 2023 Planned End Date changed from 1 Apr 2024 to 15 Apr 2024.
- 21 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 15 Apr 2024.
- 15 May 2023 Planned End Date changed from 1 Dec 2024 to 1 Apr 2024.